Synbionik designs and creates genetically modified microorganisms and matching bioreactor systems for the production of chemical compounds. This biosynthetic approach leads to drastic cost, purity, and sustainability advantages over traditional production or extraction methods. Synbionik fully embraces advanced laboratory automation technologies with the goal of realizing significant productivity advantages as one of the earliest fully committed adopters in Europe. We currently focus our efforts on the biosynthetic production of cannabinoids. This includes but is not limited to cannabidiol (CBD), cannabigerol (CBG), and tetrahyrocannabinol (THC). Behind the scenes, we are working on other products in our R&D pipeline. Watch this space for updates. Synbionik was founded in early 2019. Its headquarters are in Frankfurt/Main, Germany.